Full Report

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

How This Business Actually Works

Waaree is India's largest solar PV module manufacturer — a high-volume assembly business riding a structural demand wave. The economic engine is simple: buy solar cells (mostly imported from non-Chinese sources), glass, aluminum frames, and encapsulants; assemble them into modules at five Indian factories plus a US facility; sell to utilities, IPPs, C&I customers, retail rooftop buyers, and export markets. The company is transitioning from a pure assembler to a vertically integrated player — backward into cells (5.4 GW operational), ingots and wafers (10 GW planned by FY27), and forward into EPC, inverters, battery storage, and green hydrogen.

What actually drives incremental profit is not just volume — it's the mix. Three margin layers exist: (1) basic non-DCR modules for institutional domestic buyers at ~18-19% EBITDA margins, (2) DCR (Domestic Content Requirement) modules using Waaree's own cells at 300-350 bps higher margins, and (3) export modules to the US at 26-30 cents/Wp realization versus 16-17 cents domestic, plus IRA manufacturing credits at 7 cents/Wp. As own-cell capacity ramps and the DCR share grows, the blended margin structurally improves — which explains the OPM expanding from 4% in FY21 to 25% in Q3 FY26.

The revenue trajectory is extraordinary — from $26M in FY20 to $169M in FY25, a 49% sales CAGR — but what matters more is that margins expanded simultaneously. This is not a commodity assembler chasing volume; it's a manufacturer gaining operating leverage, product mix improvement, and backward integration benefits all at once.

The margin step-up from ~14-15% to 23-25% is not cyclical noise — it reflects own-cell integration, higher DCR mix, scale leverage from 1 GW/month production, and improving US profitability. Management's FY26 EBITDA guidance of $64-70M is being surpassed; 9M FY26 EBITDA already touched $51M.

The Playing Field

Waaree's dominance is a function of scale, not technology. In a market where India's total module capacity has surged from 38 GW (Mar 2023) to over 200 GW (Dec 2025), what separates the winner is execution speed, order book depth, and the ability to integrate backward into cells at scale.

What the peer set reveals:

Premier Energies is the closest pure-play comparator and the one to watch. Higher OPM (27%) and ROCE (41%) than Waaree, driven by cell-first strategy and dominant position in solar cell exports. Premier is scaling fast but at one-third of Waaree's capacity. If Premier achieves 15+ GW and closes the module gap, it becomes a genuine threat.

Vikram Solar has similar aspirations (targeting 20.5 GW by FY27) but trades at a steep premium on hope rather than execution — margins (14% OPM) significantly trail leaders. Waaree's execution advantage is widening, not narrowing.

Suzlon is not a direct competitor (wind vs solar) but competes for investor capital in India's renewable energy basket. Its turnaround is real (debt-free, 33% ROCE), but fundamentally a different business.

Waaree's advantage: 3.6x the module capacity of its nearest pure-play peer, the only Indian manufacturer with a serious US production footprint, a $640M order book providing 18+ months of revenue visibility, and an order pipeline exceeding 100 GW. The moat is not technology — Chinese panels are technically equivalent or better. The moat is policy (ALMM, DCR, BCD on imports) and scale in a protected market.

Is This Business Cyclical?

Solar module manufacturing is deeply cyclical, but the cycles are driven by policy and trade barriers, not end-demand.

Where the cycle hits:

Policy cycle (biggest driver): India's ALMM (Approved List of Module Manufacturers), BCD (Basic Customs Duty) on Chinese imports, and DCR mandates create a protected domestic market. When ALMM was temporarily suspended in 2023, module prices crashed and FY22-era margins collapsed. The policy environment is currently highly favorable: ALMM extended to cells from June 2026, DCR requirements increasing, and ingot/wafer ALMM from June 2028. This creates a multi-year tailwind — but it is government-granted and can shift.

Chinese overcapacity cycle: Global module prices collapsed 40-50% in 2023-24 as Chinese manufacturers dumped below-cost inventory. India's BCD tariff wall (40% on modules, 25% on cells) shielded domestic players, but the price floor is set by Chinese cost curves. When China's rebate policies change (export rebates on cells were eliminated in late 2025, pushing cell prices from 4-4.5 cents to 6 cents/Wp), it directly improves Indian cost competitiveness.

US trade cycle (new and dangerous): The US imposed 123% preliminary anti-dumping duties on Indian solar imports in April 2026, on top of existing ~126% countervailing duties. Total tariff burden exceeds 230%. This renders direct India-to-US module exports commercially unviable. Waaree's US factory insulates partially, but the 65% overseas share of its $640M order book is now at risk of renegotiation. Final determination expected July 2026.

Commodity cycle (manageable): Silver (under 9% of module cost), glass, and aluminum prices fluctuate but Waaree manages through back-to-back sourcing — locking input costs when orders are booked. Operating leverage offsets moderate commodity moves.

The Metrics That Actually Matter

1. OPM trajectory — The single most important metric. Module manufacturing at 4-5% OPM is a commodity slog. At 23-25% OPM, it's a high-quality industrial business. The margin expansion reflects real structural shifts (DCR mix, own cells, scale, US realization), not one-time factors. If OPM reverts below 18%, the thesis breaks.

2. Cell capacity utilization — Waaree's 5.4 GW cell facility is the key to the DCR story. Q3 FY26 averaged 56% but the exit rate hit 80%. Management is upgrading to G12R cells, targeting 85-90% utilization. Every percentage point of cell utilization directly feeds into higher-margin DCR module sales and reduces dependence on imported cells.

3. Order book to revenue ratio — At $640M against TTM revenue of $258M, the book provides 2.7x coverage. More importantly, 5-15% advances are collected on institutional orders, and retail (~20% of domestic) is cash-and-carry. The order pipeline of 100+ GW dwarfs the order book. This is not a demand-constrained business.

4. Working capital days — Negative working capital (-87 days in FY25) is the hallmark of a business that collects before it delivers. Customer advances fund operations. This is structurally powerful when combined with rapid growth — the faster Waaree grows, the more cash it generates from working capital.

5. Free cash flow vs capex — FCF turned negative (-$1.3M) in FY25 as capex surged to $80M (investing outflows). Borrowings rose from $6.6M (FY24) to $33M (H1 FY26). This is a deliberate choice: building 10 GW ingots/wafers, 15.4 GW cells, 20 GWh battery storage, 4 GW inverters, 1 GW electrolysers, and the US factory. The question is not whether capex is high — it's whether returns on these assets will match the 35% ROCE of the core business.

What I'd Tell a Young Analyst

Waaree is the clearest beneficiary of India's solar manufacturing policy wall — ALMM, BCD, and DCR collectively create a protected domestic market worth 40-50 GW of annual module demand by 2030. The company has executed brilliantly on capacity (from 2 GW to 18.7 GW in four years), margins (4% to 25% OPM), and order book ($640M). At 29x TTM earnings with 100%+ profit growth, the valuation is not absurd for a business of this quality.

What the market may be underestimating: The severity of the US trade risk. A 123% anti-dumping duty, if finalized, effectively closes the direct India-to-US export channel. Waaree's US factory provides a buffer, but 2.6 GW of US capacity is a fraction of the 65% overseas order book. The Meyer Burger acquisition signals intent to double down on US manufacturing, but execution risk is real.

What the market may be overestimating: The durability of the policy moat. India's module capacity has exploded to 200+ GW against annual installation demand of 40-50 GW. If ALMM enforcement loosens, or if 20+ manufacturers all reach scale simultaneously, pricing power evaporates. The 25% OPM is sustainable only while supply remains disciplined and policy protection holds.

Watch these triggers:

1. US anti-dumping final determination (July 2026) — binary event for the export thesis
2. Cell utilization crossing 85% sustained — validates the backward integration premium
3. Ingot/wafer commissioning by FY27 — if on time, Waaree becomes truly integrated; if delayed, capex burden rises without payoff
4. ALMM cell mandate (June 2026) — structurally positive for Waaree with India's largest cell capacity
5. Promoter holding at 64.2% with FII rising from 0.7% to 7% in one year — institutional conviction is building, but watch for supply from promoter dilution if the company needs more equity for its $160M+ capex program

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Thesis

Waaree trades at 29x TTM earnings because the market is pricing in a structural margin expansion story — from a 4% OPM commodity assembler in FY21 to a 25% OPM vertically integrated manufacturer in Q3 FY26 — with 49% revenue CAGR and negative working capital funding the growth. The single metric most likely to rerate or derate this stock is operating margin sustainability: if the 23-25% OPM proves structural (DCR mix, own cells, US production), fair value is well above the current price; if policy protection weakens or Chinese overcapacity bleeds through the tariff wall, margins revert to single digits and the stock collapses.

Quality Scorecard

Quality Score, Fair Value, Predictability, Altman Z, Piotroski F, and Beneish M data are not available for Waaree — the company listed in October 2024 and does not yet have sufficient history for these composite scores. What we can assess directly from fundamentals:

The financials tell a clean story: earnings convert to cash (CFO/NI consistently above 1.0x), the balance sheet is unlevered, and returns on capital are high. The missing ingredient is track record depth — Waaree has only been public for 18 months and its current margin profile is less than 3 years old.

Revenue & Earnings Power

Revenue grew 6.4x from FY20 to FY25 ($26M → $169M), but the real story is operating profit growing 26x ($1M → $32M). This is not a linear scale-up — it is a business whose unit economics transformed as backward integration, DCR mix, and export realization all improved simultaneously.

OPM tripled from 4-5% (FY20-22) to 19% (FY25), with the expansion accelerating as cell capacity ramped and DCR volumes grew. Net margin lagged slightly due to higher depreciation from capex, but still reached 13%.

The quarterly trajectory shows two inflection points: (1) the margin step-up from ~14-15% to 21-25% starting Q3 FY25 as own-cell integration kicked in, and (2) the revenue acceleration in H2 FY26 as module capacity crossed 1 GW/month. Q3 FY26 revenue of $84M was 119% higher YoY.

Cash Generation — Are the Earnings Real?

CFO has exceeded net income in every single year — the 5-year average CFO/NI ratio is 2.0x. This is unusual and structural: Waaree collects 5-15% advances on institutional orders and runs negative working capital (-87 days in FY25). The business generates cash before it delivers product.

FCF turned negative in FY25 ($-1M) as capex surged to $38M — driven by the 10 GW ingot/wafer plant, 15.4 GW cell expansion, US factory, and battery storage. This is a deliberate investment phase, not an earnings quality problem. Trailing 3-year FCF/NI (FY22-FY24) was 0.72x before the capex surge.

Capital Allocation

The pattern is clear: operating cash flow is being reinvested aggressively into capacity, with the gap funded by financing (IPO proceeds of ~$47M in FY25 and rising borrowings of $33M by H1 FY26). Dividends are token ($0.02/share in FY25 — a 0.06% yield). This is a growth-phase capital allocation profile — every dollar is going back into the business. The test comes in FY27-28 when the capex cycle matures and FCF should normalize.

Balance Sheet Health

The balance sheet deleveraged dramatically from D/E of 0.99x (FY21) to 0.13x (FY25) as equity expanded 27x through retained earnings and IPO proceeds, while borrowings grew modestly. However, H1 FY26 borrowings jumped to $33M (D/E ~0.26x) to fund the capex program. Still conservative for a manufacturing business of this scale, but the trend has reversed. Total assets have grown from $12M (FY20) to $277M (H1 FY26) — a 23x expansion in 5.5 years.

Valuation

Waaree listed in October 2024, so there is no multi-year valuation history to assess. The stock has traded in a $22-$41 range since listing.

At 30.8x TTM P/E, Waaree trades at a significant premium to the broader industrial sector but at a discount to Premier Energies (35.5x) and a steep discount to Tata Power (38.2x). Given 113% profit CAGR over 5 years and 100%+ YoY growth in recent quarters, the PEG ratio is well under 1.0x — suggesting the growth rate more than justifies the multiple. The risk is that this growth rate is decelerating faster than the market expects, particularly if US tariffs choke the export channel.

Peer Comparison

Waaree's closest pure-play comparator is Premier Energies, which commands a 15% P/E premium (35.5x vs 30.8x) on higher margins (27% vs 19% OPM) and superior ROCE (41% vs 35%). The premium is justified by Premier's cell-first strategy. But Waaree's 3.6x capacity advantage and $640M order book provide scale that Premier cannot match. The IPP/utility peers (Adani Green, NHPC, Tata Power) are not comparable — they are asset-heavy power generators, not manufacturers.

Fair Value & Scenario Analysis

Given the limited listed history, fair value estimates rely on earnings-based methods and analyst consensus.

Analyst consensus clusters around $38-$45 (Emkay, Motilal Oswal, Prabhudas Lilladher), implying 3-22% upside. The consensus assumes continued execution and manageable US tariff impact. The bear case is not remote — a 123% anti-dumping duty, if finalized in July 2026, would structurally impair the export thesis and force order book renegotiation on 65% of overseas orders.

Shareholding Evolution

The most striking shift: FII holdings surged from 0.7% (Mar 2025) to 7.1% (Mar 2026) — a 10x increase in institutional foreign ownership in one year. DII also doubled from 2.5% to 4.3%. Promoter holding remains stable at 64.2%. This institutional accumulation signals growing conviction from sophisticated capital, but also creates a potential overhang if the US tariff situation worsens.

What the Numbers Say

The numbers confirm that Waaree is a genuinely transformed business — not just a volume play, but a manufacturer with real margin expansion, exceptional cash conversion, and a balance sheet that can fund its ambitions — and contradict any residual narrative that this is a commodity assembler trading on hope, since every financial metric (CFO/NI, working capital, ROCE, margin trajectory) shows structural quality improvement. Watch the Q4 FY26 results (today, April 29) and the US anti-dumping final determination (July 2026) — together they will determine whether the 25% OPM and export revenue base survive into FY27, which is the entire ballgame for the valuation.

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Where We Disagree With the Market

The market is debating the wrong variable. Consensus treats Waaree's 25% OPM as either "structural from cell integration" (bull) or "policy artifact from ALMM/BCD" (bear), and both sides focus on the US tariff stack as the swing factor. Our evidence suggests neither framing captures the decisive shift: the ALMM cell mandate (June 2026) is about to create a domestic cell oligopoly — 27 GW of qualifying cell capacity serving 165 GW of module demand — and Waaree owns 20% of the bottleneck. The market prices this as "generally positive for Indian solar." It is specifically transformative for the three to four companies with qualifying cell lines, and it means that domestic margin power may actually increase even as the US export channel degrades. The resolution comes fast: post-June 2026 DCR module pricing and Q1 FY27 OPM will tell us whether cell scarcity translates into margin expansion or gets competed away.

Variant Perception Scorecard

Variant strength is moderate-to-high at 62. The cell oligopoly thesis is material and testable, but conditional on ALMM enforcement rigor and whether the 27 GW cell figure holds (new entrants could qualify). Consensus clarity is 70 — the bull/bear split is observable in the Kotak SELL ($27) versus Emkay BUY ($45) spread, but neither side has explicitly modeled the cell bottleneck as the primary margin driver. Evidence strength is 65 — ICRA, Wood Mackenzie, and Motilal Oswal all flag overcapacity at the module level, but the cell constraint is quantifiable only from ALMM-II registration data. Resolution is 2-3 months: June 2026 ALMM cell mandate enforcement and July 2026 US AD final determination together collapse the uncertainty window.

Consensus Map

The Disagreement Ledger

Disagreement 1 — Cell oligopoly mispricing. Consensus would say the ALMM cell mandate is a general tailwind for Indian solar manufacturing, benefiting all domestic players with cell capacity. Our evidence disagrees: India will have 165 GW of module capacity by March 2027 (per ICRA) but only 27 GW of ALMM-qualifying cell capacity (per Motilal Oswal). That is a 6:1 module-to-cell ratio. Module-only manufacturers face a structurally oversupplied market (60-65 GW annual output vs 45-50 GW annual demand per ICRA). But cell-integrated players control the bottleneck — every solar project commissioned after June 1, 2026 must use domestic-cell modules. Waaree owns 5.4 GW of this 27 GW bottleneck — roughly 20%. If the market concedes this is a margin concentrator and not just a policy tailwind, the DCR premium should widen materially beyond the current 300-350 bps. The cleanest disconfirming signal would be 10 or more manufacturers qualifying on ALMM List-II with combined capacity exceeding 50 GW, diluting the bottleneck.

Disagreement 2 — US tariff and domestic cell mandate as partial offsets. A consensus bear would say: US tariffs destroy 35% of revenue (direct exports) while domestic overcapacity (165 GW vs 45-50 GW demand) compresses margins on the remainder. Our evidence complicates this: the US tariff wall forces Indian manufacturers to redirect capacity toward the domestic market, which increases module-level competition. But the ALMM cell mandate simultaneously creates a domestic cell bottleneck that benefits the exact same cell-integrated players being hurt by US tariffs. Waaree's cell assets become more valuable domestically precisely when the US channel closes. If we are right, the bear-case $26 floor (based on 15% OPM on compressed revenue) is too pessimistic — the domestic cell premium should support 18-20% OPM even in a US-impaired scenario. The disconfirming signal: if cell capacity additions accelerate so fast that the bottleneck evaporates by FY28, the offset disappears.

Disagreement 3 — Order book renegotiation timing. Consensus reacted to the CVD and AD announcements as immediate impairment events — the stock dropped 10.4% and 5% on respective trading days. But order book renegotiation in the solar industry is not instantaneous: contracts carry advance payments (5-15%), bilateral terms require mutual agreement, and the 2.6 GW US factory (expanding with Meyer Burger's 1 GW) can absorb a portion of US-bound orders at IRA-credit-enhanced margins. The market may be front-loading 12-18 months of gradual drag into single-day price drops. If correct, the tactical implication is that tariff headline sell-offs create entry points. What would make us wrong: if major customers invoke force majeure or walk away from advances, converting a drag into a cliff.

Evidence That Changes the Odds

How This Gets Resolved

What Would Make Us Wrong

The cell oligopoly thesis rests on two pillars: that ALMM-II enforcement is strict and that qualifying cell capacity remains scarce. If the government publishes an ALMM List-II with 10 or more manufacturers and total qualifying cell capacity exceeding 50 GW, the bottleneck dissolves and there is no pricing power to concentrate. This is plausible: India's cell capacity has been expanding rapidly (projected 70 GW by March 2027 per ICRA), and the distinction between "installed capacity" and "ALMM-qualifying capacity" may narrow as manufacturers upgrade and certify. The 27 GW figure from Motilal Oswal may already be stale by June 2026.

The US tariff offset thesis assumes that domestic cell pricing power compensates for lost US export margin. But the domestic solar market is not a static pool — 45-50 GW of annual installations is growing, but so is the installed base of module capacity (165 GW). If installations disappoint (policy delays, land acquisition bottlenecks, transmission constraints), even cell-integrated players face volume pressure. The 60-65 GW annual module output against 45-50 GW demand means even cell-scarce manufacturers will compete aggressively on non-DCR modules, depressing blended realisations. If Waaree's domestic volume cannot replace US volume, the net effect is still margin compression — just less severe than the bear case implies.

The timing thesis (gradual drag, not cliff) could also be wrong. Indian solar export contracts may not be as sticky as we assume. If US customers have tariff-adjustment clauses or if financing conditions force renegotiation, the order book could reprice faster than 12-18 months. The CBP EAPA investigation adds a parallel risk: an adverse finding could trigger retroactive duty assessments on historical imports, converting a forward-looking drag into a backward-looking liability.

Finally, the entire variant rests on policy continuity. The ALMM cell mandate, BCD, and DCR are government-granted protections that have been suspended before (2023 ALMM suspension cratered OPM to 4%). A political shift, a bilateral trade deal with the US, or a government decision to prioritise installation speed over domestic manufacturing could undermine the cell oligopoly before it fully materialises.

The first thing to watch is the ALMM List-II publication — the number of qualifying manufacturers and their total cell capacity will determine within days whether the 6:1 bottleneck is real or already eroding.

Bull and Bear

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Verdict: Watchlist — both decisive variables resolve inside 60-90 days, so pre-positioning is gambling on a binary outcome. Bull has the stronger backward-looking record (five consecutive quarters at 21-25% OPM, CFO/NI 1.9x, FII float up 10x), but the entire structural-margin claim is hostage to two near-term events: ALMM cell-mandate enforcement (June 2026) and the US anti-dumping final determination (July 2026). Bear's concrete evidence — 230%+ tariff stack on a 41%-US order book, an active CBP EAPA investigation into the exact supply-chain reconfiguration management is now executing, simultaneous CEO+CFO exit, $2.6+ B capex into seven pre-revenue verticals — is enough to defer commitment until the July print. The single tension that decides everything: is the 25% OPM structural (cell integration + scale) or a policy artifact (ALMM/BCD/DCR)? A Q1 FY27 OPM in the 22%+ band post-AD-final flips this to Lean Long; a print under 18% confirms Bear.

Bull Case

Bull target $51 over 12-18 months on 26x FY27E EPS of ~$1.96 (FY27E PAT $565 M at $3.73 B revenue × 23% OPM), reflecting a discount to Premier Energies (35.5x) for US regulatory risk and a premium to Suzlon (24x) for margin profile. Primary catalyst: ALMM cell-mandate enforcement in June 2026. Disconfirming signal: Q4 FY26 / Q1 FY27 OPM falling below 18% on a sustained basis would invalidate the structural-margin frame.

Bear Case

Bear downside $26 over 12-18 months on 22x margin-compressed FY27E EPS of ~$1.15 (OPM reverts to 15% on ~$2.98 B revenue post-US haircut, PAT ~$330 M); cross-checked against Kotak SELL target of $27. Primary trigger: July 2026 US AD final determination confirming the 230%+ stack and forcing renegotiation of the US-tied book (~41% of total). Cover signal: OPM sustains above 22% for three consecutive quarters after the final determination, with US-factory revenue demonstrably replacing India-to-US exports at comparable margins.

The Real Debate

Verdict

Watchlist. Bull carries slightly more weight on the empirical record — five consecutive quarters of 21-25% OPM and CFO/NI of 1.9x are not easily dismissed as policy artifacts, and the FII float jump from 0.7% to 7.06% reflects sophisticated capital underwriting that record. The single most important tension is the source of the 25% OPM: structural (cell integration + scale) or policy-granted (ALMM/BCD/DCR). Bear could still be right because the entire margin stack rests on protections that have collapsed before — OPM was 4% during the 2023 ALMM suspension — and a 230%+ US tariff wall on 41% of the order book is binary risk that cannot be hedged with the current 2.6 GW US footprint. The verdict flips to Lean Long if Q4 FY26 or Q1 FY27 OPM prints ≥22% after ALMM cell-mandate enforcement (June 2026) and the July 2026 AD final determination, with US-factory revenue visibly replacing India-to-US exports at comparable margins; it flips to Lean Short / Avoid Ownership if OPM falls under 18% or the CBP EAPA case results in retroactive-duty findings on past shipments. With both decisive events inside 60-90 days, waiting for the print is the institutional move.

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Catalyst Setup

The next six months hinge on two binary regulatory events — the US anti-dumping final determination (expected July 2026) and the ALMM cell mandate enforcement (June 1, 2026) — that together will determine whether Waaree's 23-25% OPM is sustainable or policy-fragile. Today's Q4 FY26 results and simultaneous board consideration of a QIP/GDR/FCCB fundraise add near-term event density. The catalyst calendar is unusually busy for an 18-month-old listing: five hard-dated events within 90 days and at least three more high-impact items before October 2026. The key question is not growth — that is visible in the $5.2-6.4B order book — but whether the US export channel survives and whether domestic margins hold as ALMM enforcement reshapes competitive dynamics.

Ranked Catalyst Timeline

Impact Matrix

Next 90 Days

The next 90 days (through late July 2026) contain the three highest-impact catalysts for Waaree — an unusually dense window for a single stock.

What Would Change the View

The investment debate on Waaree will be resolved by three observable signals over the next six months. First, the US anti-dumping final determination (July 2026): if the 123% preliminary rate is confirmed or raised, the India-to-US export channel is permanently impaired and the bull thesis must be rebuilt entirely around domestic demand — at materially lower realization (16-17 vs 26-30 cents/Wp). If the rate is substantially reduced, the stock likely breaks its all-time high as the single largest overhang lifts. Second, post-ALMM cell mandate OPM trajectory: the bull case rests on margins being structural (driven by backward integration and DCR mix), not cyclical (driven by trade barriers alone). If OPM holds above 22% through Q1-Q2 FY27 — a period that will reflect both ALMM enforcement and post-tariff export mix changes — the margin story is validated. If OPM drops below 18%, the bear case that these are policy-granted margins is confirmed. Third, capex execution versus dilution: the QIP/GDR decision today, combined with the ingot/wafer commissioning timeline, will reveal whether Waaree can fund $2.7B+ of capex from operating cash flow plus modest leverage, or whether ongoing equity dilution is required. A company that can self-fund its integration at 35% ROCE is worth a premium multiple; one that dilutes every 18 months to fund pre-revenue adjacencies is not.

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Full Story

Waaree Energies transformed from a low-margin module assembler into India's largest integrated solar manufacturer in under four years, riding a combination of government policy tailwinds, US export demand, and aggressive backward integration. Management's narrative evolved from "we make cheap solar panels" to "we are the energy transition platform" — and margins followed, expanding from 4% to 25%. The credibility question is no longer whether they can grow, but whether the Waaree 2.0 diversification story (batteries, hydrogen, transformers, inverters) will deliver returns anywhere close to the solar core, and whether the US regulatory overhang will become material.

---

1. The Narrative Arc

The inflection point was FY2023: US export demand surged under anti-dumping pressures against Chinese/SE Asian modules, and Waaree's India-origin products became attractive. Revenue jumped from $38M to $82M in a single year. But the real structural shift came in FY2025-26 when backward integration into cells started compressing input costs, and DCR (Domestic Content Requirement) policy created a protected premium market for Indian-made cells.

The Q3 FY25 margin jump from 15% to 21% was the moment the story changed. It coincided with falling cell input costs and management's shift toward "choosing profitable orders." Every quarter since has held or expanded.

---

2. What Management Emphasized — and Then Stopped Emphasizing

What rose: "EBITDA as North Star" did not exist before Q4 FY25. Once management gave formal guidance ($643-702M), it became the single most repeated phrase in every subsequent call. The DCR/ALMM theme escalated as cell capacity came online — it went from background policy to a core margin driver.

What faded: The "multi-decadal growth story" framing — repeated four times in the maiden Q2 FY25 call — gradually became assumed rather than argued. IRA discussion peaked when Trump won in late 2024, then management deliberately steered away: "we don't bake in PLI" became the talking point, and IRA was reframed as "cherry on the top."

The quiet pivot: Export mix. In Q2 FY25, management acknowledged exports dropped from 60% to 27% of sales and called it "just a point in time" and "definitely not because of competition." By Q4 FY25, they repositioned the domestic-heavy mix as strategic: 80% domestic, 17-22% exports, and framed it as a feature rather than a limitation.

---

3. Risk Evolution

The risk profile has shifted dramatically. In FY25, the dominant investor concern was IRA removal under Trump. Management neutralized this by (a) positioning the US factory as "making in America for America" and (b) demonstrating 80% domestic revenue. By Q3 FY26, IRA had faded and two new risks emerged:

AD/CVD investigation (new): CBP probe into cell sourcing for US-bound modules. Management acknowledged it openly, provisioned $33M proactively, and stated "our internal review suggests we may not be facing a whole host of liabilities." The proactive provisioning was a credibility-positive move.

Silver/commodity prices (new): Q3 FY26 brought sharp investor questions about silver (25% of cell cost) and China export-rebate removal pushing cell prices from ¢4-4.5 to ¢6. Management response: "less than 9% on a module basis" and offset by operating leverage. This risk was not discussed before FY26.

---

4. How They Handled Bad News

The export mix collapse (Q2 FY25): Exports dropped from 60% to 27% of sales. CEO Amit Paithankar: "The reduction is definitely not because of competition. It is actually just a point in time." This was partially honest — the order book was 72% US — but it sidestepped that US execution timelines were 1-2 years out. By Q3 FY25, as domestic margins improved sharply, the narrative shifted to this being a superior mix.

Cell factory ramp-up delays: Promised 1.4 GW by Dec 2024, full 5.4 GW by March 2025. Reality: by Q2 FY26, cell utilization was still under 15% on a quarterly basis. Management consistently framed it as "ramp-up changes almost on a daily basis" and by Q3 FY26 said "most of the teething trouble is behind us" with current run-rate at 80%. The 9-month lag between COD and meaningful utilization was never acknowledged as a delay.

US AD/CVD probe (Q2-Q3 FY26): Handled well. Acknowledged transparently: "I definitely confirm that the probe is on." Provisioned $33M on lawyer advice before any demand was raised. This was the most credibility-enhancing moment in the transcript record.

---

5. Guidance Track Record

Management consistently delivers on financial outcomes (margins, EBITDA) but has a pattern of optimistic timelines on manufacturing ramp-ups. The cell factory was declared "commercially operational" months before meaningful utilization materialized. The EBITDA guidance, however, has been the strongest credibility anchor — given in Q4 FY25 at $643-702M and on track to be exceeded with 9M at $489M.

---

6. What the Story Is Now

The current narrative is "Waaree 2.0" — a transition from India's largest solar module maker into an integrated energy transition platform spanning polysilicon (Oman JV), ingots/wafers, cells, modules, inverters, transformers, batteries (20 GWh), green hydrogen (1 GW electrolyser), and power infrastructure (6.1 GW connectivity secured).

What has been de-risked:

The core solar manufacturing business. OPM expanded from 4% to 25% over five years, and the EBITDA guidance delivery builds institutional credibility

Cell backward integration. Despite slow ramp, own cells now running at 80% utilization and feeding DCR market at higher margins (300-350 bps uplift)

US manufacturing presence. 2.6 GW module capacity in US (including Meyer Burger acquisition) provides tariff hedge

Order book visibility. $6.4B with 5-15% advances and 65% overseas, providing 2+ years of revenue visibility

What still looks stretched:

The Waaree 2.0 diversification. $2.7B+ capex into BESS, hydrogen, transformers, smart meters — all pre-revenue. Management says payback in 3-5 years with "similar ROCE" but has zero operating history in these segments

Capital allocation discipline. Acquisitions accelerating (Enel, Kotsons, Racemosa, Meyer Burger) while core capex is $2.7B+. Management declined to give FY27 EBITDA guidance

US regulatory tail risk. AD/CVD probe ongoing, $33M provisioned, and US anti-dumping duties on Indian solar announced Apr 2026. The 14% + 26% tariff structure creates ongoing uncertainty for India-to-US exports

Cell/ingot-wafer execution. 10 GW cell + 10 GW ingot-wafer by FY27 is ambitious. Each GW of cell takes 4-6 months to ramp per management's own admission

What to believe vs. discount:

Believe: The India domestic solar story. 35 GW installed in 9M FY26, heading to 60-70 GW annually by decade end. Waaree's 14% market share, DCR cell advantage, and 400+ retail channels position it well

Believe: The EBITDA guidance. Management has earned credibility here and the 9M trajectory supports it

Discount: Revenue/margin projections for BESS, hydrogen, transformers. These are embryonic and management itself says "to give you hard numbers which are of audit grade will probably not be possible"

Watch: US revenue share. Currently 17-22% of sales but 55-65% of order book. How this converts — and at what margin after tariffs — is the key swing variable for FY27-28

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Financial Shenanigans

Waaree Energies earns a Forensic Risk Score of 48 — Elevated. The core reported financials pass most earnings-quality tests: operating cash flow exceeds net income consistently (1.6x in FY25, 1.9x three-year average), accrual ratios are negative, and debtor days are stable. However, three linked concerns pull the score into elevated territory: (1) a live US Customs and Border Protection investigation (EAPA Case 8163, initiated September 2025) alleging evasion of anti-dumping duties on solar cells, which carries material legal, financial, and reputational risk; (2) volatile and opaque other income that inflated FY24 earnings by $6.9M (37% of operating profit); and (3) promoter-dominated governance with an executive director on the audit committee. The single data point that would most change this grade is the outcome of the CBP investigation — an adverse finding could push the score to High; resolution without penalty would bring it toward Watch.

---

Breeding Ground

Waaree's governance structure creates moderate breeding-ground risk — not because of documented misconduct, but because the structural conditions that make shenanigans easier to execute are present.

The Doshi family controls 64% of shares and occupies two of four executive board seats. The Chairman and Managing Director, Dr. Hitesh Doshi, has served since 2007 and holds the CSR committee chair. His brother Viren is a whole-time director with 67% board meeting attendance in FY25 — the lowest on the board. An executive director (Hitesh Mehta) sits on the audit committee, which while permitted under Indian regulations, weakens the independence of the oversight function. These are common patterns in Indian promoter-led companies and do not by themselves indicate misconduct. However, they reduce the institutional friction that would slow or surface accounting aggression if it occurred.

The auditor is SRBC & Co LLP (EY network), a top-tier firm. No qualification, emphasis of matter, or adverse observation has been reported. Auditor non-audit fees are modest in absolute terms but the ratio (56% of audit fees) plus $0.46M in IPO-related fees is worth monitoring. The CARE A+ / A1+ credit rating upgrade validates external comfort with credit quality.

The most significant breeding-ground signal is management's explicit EBITDA-guidance approach. CEO Amit Paithankar stated on the Q4 FY25 call: "Our key control variable is going to be EBITDA. And that's going to drive how we are going to manufacture." When the primary incentive metric is a non-GAAP measure, the classification of items between operating and non-operating, and between revenue and other income, becomes a more sensitive forensic question.

---

Earnings Quality

Reported earnings pass most quality tests, but elevated other income and the CBP investigation create two distinct areas of concern.

Revenue growth vs receivables: Clean. Debtor days were 31 in FY24 and 30 in FY25 on 27% revenue growth. This is a strong signal that revenue is being collected, not parked in receivables. The retail segment operates on a "book and ship" basis with full payment before shipment, per management's Q4 FY25 commentary.

Other income: Yellow flag. Other income has been volatile and material. In FY24, it reached $6.9M — 37% of operating profit and 45% of pre-tax profit. Within FY24, $4.4M (63% of the annual figure) landed in Q4 alone. By FY25, other income dropped to $4.7M (15% of operating profit), and in Q3 FY26, it turned negative at -$1.1M. The company has not clearly disclosed the composition of other income in investor presentations. Possible components include interest income on IPO proceeds parked in term deposits, IRA (Inflation Reduction Act) manufacturing credits from the US facility, foreign exchange gains/losses, and investment income. The Q3 FY26 negative figure suggests FX losses or mark-to-market reversals.

The Q4 FY24 spike is forensically significant because it coincided with a quarter where operating profit ($5.0M) was the weakest of H2 FY24. Without the $4.4M other income, PBT would have been $3.5M instead of $7.9M — a 55% haircut. This does not prove manipulation, but it demonstrates that FY24 bottom-line quality was materially dependent on below-the-line items.

Margin expansion: Appears operationally driven. OPM expanded from 14% (FY24) to 19% (FY25) and further to 23-25% in recent quarters. This is supported by: (a) 5.4 GW cell production coming online, reducing procurement costs; (b) operating leverage on higher volumes (module production up 94% YoY in Q3 FY26); (c) favorable DCR (Domestic Content Requirement) pricing for Indian-cell modules at ~$0.27/watt. The CFO confirmed back-to-back hedging on commodity procurement against orders, limiting gross margin volatility.

Capex and capitalization: Requires monitoring. Fixed assets grew from $17.4M (FY24) to $47.4M (FY25), with CWIP at $22.0M. Depreciation was $4.7M on an asset base that averaged ~$32M during the year. Capex-to-depreciation is running at approximately 8x, which is elevated but expected during a capacity-building cycle (6 GW wafer-cell-module, US expansion, battery facility, electrolyzer plant). The question is whether all capitalized amounts represent productive assets or whether any operating costs are being parked in CWIP. The rapid timeline of multiple concurrent megaprojects warrants investor scrutiny as they become operational.

---

Cash Flow Quality

Operating cash flow is strong and passes core quality tests, but free cash flow turned negative in FY25 as the capex cycle accelerated.

CFO/NI is healthy. The three-year average (FY23-25) is 1.90x — net income is well-supported by cash generation. FY25 alone was 1.64x. This ratio has declined from 3.12x in FY23 as the profit base expanded, but it remains above 1.0x, which is the critical threshold.

FCF turned negative in FY25. Free cash flow (CFO minus capex) was -$1.3M as capex consumed $38.3M (CFI was -$79.6M but includes investments and acquisitions). This is entirely explained by the capacity expansion: 5.4 GW cell plant, US facility ramp-up, 6 GW wafer-cell-module complex, and multiple adjacent ventures (batteries, inverters, electrolyzers). The IPO raised significant capital specifically for these purposes, and the CARE monitoring report confirmed IPO proceeds are being deployed as stated with unutilized amounts in term deposits.

Working capital contribution: Clean. DPO was 91 days in FY25 versus 84 days in FY24 — a modest increase, not a payable-stretching alarm. Inventory days improved from 108 to 96. The cash conversion cycle contracted from 55 to 35 days. There is no evidence of unsustainable working-capital lifelines propping up CFO.

No evidence of factoring or securitization. Management stated on earnings calls that retail orders are shipped only after full payment, and project orders carry 5-15% advances. There is no disclosure of receivable sales programs or supplier finance arrangements.

Financing inflows are transparent. The $47.2M CFF in FY25 is primarily attributable to IPO proceeds and incremental borrowings (from $6.6M to $14.0M). No boomerang transactions or disguised financing observed.

---

Metric Hygiene

The primary metric concern is the centrality of EBITDA guidance to the investment narrative. While EBITDA is a legitimate operating metric, Waaree's definition has not been independently audited as a non-GAAP reconciliation. The CFO stated EBITDA is calculated as "profit before taxes plus finance costs, depreciation, and amortization" — a standard formulation. However, the inclusion or exclusion of other income (IRA credits, FX, investment income) creates a grey zone. On the Q4 FY25 call, CEO Paithankar explicitly said the EBITDA guidance does not include "exceptional other income," but $1.6M of other income was reported in Q4 FY25 itself.

No metrics have been discontinued or redefined between periods. The order book disclosure has been consistent in format. These are positive hygiene signals.

---

What to Underwrite Next

Highest-priority items to track:

1. CBP EAPA Case 8163 outcome. Monitor quarterly for interim measures, final determination, and potential duty assessments. A finding of duty evasion would require: (a) restatement of import duties, (b) potential penalties, (c) impairment of US order book, and (d) reputational spillover to other markets. The signal that would downgrade the forensic grade to High: CBP issues a final affirmative determination with duty assessments exceeding $12M.

2. Other income composition. Demand disclosure of other income breakdown: interest income, IRA credits, FX gains/losses, investment gains, and any related-party items. Track whether Q3 FY26's -$1.1M signals a structural reversal or one-time FX hit.

3. Cell utilization trajectory. The 5.4 GW cell plant operated at 56% utilization in Q3 FY26 (though management claimed 80%+ run-rate as of January 2026). If utilization stalls, the margin expansion story falters and capitalized costs become harder to justify.

4. CWIP-to-asset conversion. $22.0M CWIP in FY25 and $21.3M in H1 FY26. Monitor whether CWIP declines as projects reach commissioning dates (FY27 target for wafer-cell-module complex, batteries, electrolyzers). Persistent or growing CWIP relative to commissioning timelines would be a yellow flag.

5. IPO proceeds utilization. CARE monitoring report confirms partial deployment. Track deviation from stated objectives, particularly the $33.3M earmarked for the Odisha facility.

Signal that would upgrade the grade: CBP investigation resolved without penalty; cell utilization exceeds 85% sustained; other income stabilizes as a small percentage of PBT; CWIP converts to revenue-generating assets on stated timelines.

Signal that would downgrade the grade: CBP adverse finding; other income proves to include undisclosed related-party items or recycled gains; cell plant utilization stalls below 70%; CWIP grows without corresponding asset commissioning; auditor issues emerge.

The accounting risk at Waaree is not a thesis breaker — it is a position-sizing limiter. The core business (modules + cells) generates genuine cash from real manufacturing activity, and CFO/NI ratios confirm this. But the CBP investigation adds a binary legal risk that is difficult to underwrite, the other-income volatility makes quarter-to-quarter earnings comparisons unreliable, and the promoter-dominated governance reduces the institutional check on capital allocation as the company deploys $175M+ across multiple megaprojects simultaneously. An investor comfortable with the business thesis should haircut the US order book contribution, normalize for other-income volatility, and track CWIP conversion as the primary near-term forensic indicators.

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The People

Governance grade: B+. Exceptional promoter alignment (64% ownership, zero pledge, no insider selling) is offset by CEO churn, a complex multi-entity group structure, and rapid diversification into adjacencies that will test capital allocation discipline.

The People Running This Company

The Doshi family built this company from a $1 loan in 1985 to India's largest solar module manufacturer. Chairman Hitesh Doshi remains the strategic centre of gravity, while day-to-day operations have transitioned to a new CEO — the second in under two years.

The real power still resides with Hitesh Doshi. The professional CEO is an execution layer; strategic direction — including the $2.7B capex plan, US expansion, battery foray, and acquisition spree — is driven by the founder-chairman.

What They Get Paid

Total executive pay of $4.13M is 1.8% of FY25 net profit ($226M) — reasonable for a $10.7B market cap company growing profits at 113% CAGR. The CMD's $1.16M package is modest given his family's $6.9B stake — his real compensation is equity appreciation, not salary.

Hitesh Mehta's $1.03M ESOP grant makes him the highest-paid executive. The ESOP 2021 plan was ratified by shareholders with 97.61% approval via postal ballot in March 2025 — no governance concern here. No ESOPs were granted to non-executive or independent directors.

Independent directors received only sitting fees ($0.02-0.03M each), with no stock options or commissions. This is clean.

Are They Aligned?

Ownership and control: The Doshi family holds 64.19% through the promoter group. Promoter holding has been rock-steady — declining just 0.12% in the past year (likely ESOP dilution, not sales). There are zero pledged promoter shares. This is a founder-operator company where the chairman's personal wealth is overwhelmingly concentrated in Waaree stock.

Insider buying / selling: No insider trading disclosures since 2015 per SEBI regulations. The promoters have neither bought nor sold shares in the open market. A March 2026 transfer by Chimanlal Tribhuvandas Doshi (promoter group member) to Shri Mahavira Jaina appears to be a charitable/trust transfer, not a market sale.

Institutional validation: FII holdings surged from 0.7% to 7.06% in a single year — a strong endorsement. DII holdings also doubled from 2.46% to 4.32%. Retail shrunk from 32.5% to 24.4% as institutions accumulated.

Dilution: The company issued equity for the IPO (October 2024) and raised $107M via equity for the battery venture. Total shares outstanding grew from ~263M (FY24) to ~287M (FY25) — roughly 9% dilution. The ESOP 2021 plan adds incremental dilution but was overwhelmingly approved by shareholders. No warrants or convertible instruments outstanding.

Related-party behaviour: The Waaree Group operates through multiple listed entities: Waaree Energies (parent), Waaree Renewable Technologies (subsidiary, EPC), and Indosolar (subsidiary, PV cells). Directors Hitesh Doshi and Viren Doshi sit on boards of all three. Waaree Energies recently offloaded 14.66% of Indosolar via OFS (Sept 2025) and acquired 64% of Kotsons (transformers) for $22M. The group is on an acquisition spree: smart meters (Racemosa), inverters (Ewaa), transmission towers (Associated Power Structures for $131M via WRT). These intra-group transactions are disclosed but add complexity. No SEBI actions or shareholder dissent flagged.

Capital allocation: $2.7B capex guided across cells, wafers, polysilicon (via United Solar Holdings in Oman), batteries (20 GWh), inverters, transformers, and electrolysers. This is aggressive. Free cash flow turned negative in FY25 (-$13M) despite $369M operating cash flow — the investment cycle is in full swing. Dividend payout is essentially zero (0.06% yield).

Exceptional ownership alignment (64%, no pledge, no selling). Dinged for: zero dividend, aggressive capex funded partly by dilution, CEO churn, and complex group structure.

Board Quality

Independence assessment: The board is 50/50 executive-to-independent, meeting SEBI requirements. The audit committee is chaired by R.M. Malla, an ex-banker with 5 other listed board seats, and met 10 times — well above the minimum. NRC is chaired by Richa Goyal, the sole woman director, who sits on 5 other listed boards.

Strengths: High attendance across independent directors (100% for Malla and Goyal). Active audit committee with external internal auditor (Mahajan and Aibara). Independent directors' meeting held separately to evaluate the Chairman. Board evaluation process is in place.

Weaknesses: Only one woman on a board of eight (12.5%). No independent director has deep solar/renewable energy operating experience — skills are generic (financial, risk, governance). The board age profile skews old (75% in the 56-75 bracket). Viren Doshi's 67% attendance stands out as poor for a promoter-director.

Missing expertise: Technology/R&D depth (critical for a company investing in next-gen solar cells, batteries, and electrolysers), and international regulatory expertise (critical given US trade exposure — 123% anti-dumping duty announced April 2026).

The Verdict

What would cause an upgrade: Two to three years of disciplined capital allocation with consistent ROCE above 25%. The new CEO Jignesh Rathod establishing credibility over a full annual cycle. Simplification of group structure (e.g., delisting or merging Indosolar/WRT into the parent). Board addition of a genuine solar technology expert and a second woman director.

What would cause a downgrade: Another CEO departure within 12 months. Material related-party transactions benefiting group entities at the parent's expense. Promoter share pledge or significant insider selling. ROCE declining below 20% as capex ramps. Adverse SEBI action on governance or insider trading practices.

Web Research

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Bottom Line from the Web

Two storylines dominate the web that the filings under-describe. First, Waaree's US franchise — 30-35% of revenue and ~41% of order book — is under simultaneous tariff, anti-dumping, and US-CBP origin-fraud scrutiny, with a 125.87% countervailing duty announced 26 Feb 2026 and a stock that fell 10.4% in a single session. Second, the company is mid-pivot from solar pure-play to multi-product clean-energy platform — board approved $920M capex (Oct 2025) for BESS/electrolyser/inverter plus $416M glass capex (Mar 2026) — while replacing both CEO and CFO in March 2026. The street is split: Kotak SELL at $30 against an Emkay BUY at $45; FII ownership has nonetheless surged from 0.7% to 7.06% in 12 months.

What Matters Most

1. US tariff stack is now an existential risk to ~one-third of revenue

2. CEO and CFO out together at peak controversy

3. ~$1.36B non-solar capex commitments quietly redefine the company

4. FII ownership jumped 10x even as US risk crystallised

5. Reliance and Adani entering solar manufacturing post-FY27 = domestic overcapacity overhang

6. Order book triples 2024-2025 to $5.7B; pipeline above 100 GW

7. Promoter HUF dissolution moved 6.75% intra-group, exempt from open-offer

8. Kotak's SELL is the bear-case anchor; consensus is otherwise BUY

9. Texas plant — management's "crown jewel" — is now a tariff workaround, not a moat

10. Q3 FY26 print: revenue +118.8%, PAT +115.6% — earnings momentum still intact

Recent News Timeline

What the Specialists Asked

Insider Spotlight

Key insider takeaways: (1) Zero promoter pledge — clean. (2) Promoter aggregate stake fell only 12 bps in 12 months despite ~1% ESOP allotments — promoter alignment intact. (3) CEO and CFO simultaneous exit at peak US controversy is the biggest people-side flag. (4) Intra-group HUF consolidation Jun-25 used SEBI exemption to rearrange 6.75% off-market — legal but worth disclosing to ESG-sensitive funds. (5) FII 10x increase signals foreign institutional conviction despite tariff overhang.

Industry Context

Indian solar manufacturing is restructuring around three forces:

1. DCR (Domestic Content Requirement) compliance is becoming the margin moat. Nuvama estimates DCR-compliant integrated peers (Premier Energies, Websol) earn over 40% higher realisations than module-only players. Waaree's 5.4 GW cell facility (live end-Mar 2025) closes that gap; Q3 FY26 OPM hitting 25.49% supports the thesis.

2. US tariff stack is the single biggest cyclical force. Anti-dumping (Aug 2025), CBP origin probe (Sep 2025), 125.87% CVD (Feb 2026), Trump IRA pause (Jan 2025) — each event has reset valuation for Indian solar names. Waaree's Texas plant is dual-edged: a hedge under Republican domestic-content rules but exposed under "made in America" purity tests.

3. Domestic competitive structure shifts post-FY27. Reliance and Adani entering solar manufacturing represent the medium-term bear thesis (Mint Feb 2026, Kotak Jan 2025). Today's $5.71B order book with 3.2x revenue cover is the buffer Waaree has to scale before that competition lands.

Coverage gap: Three specialist queries on industry trends, peer landscape, and hiring signals returned zero web results. Peer benchmarking inferred from Tijori (Premier Energies, Websol, Insolation, Swelect, Solex, Alpex, Emmvee) and ValueResearch (industry P/E 21.07; Waaree at 46% premium).

"Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged."

Liquidity & Technicals

Waaree is institutionally tradable at moderate size: $67.8M clears in five trading days at 20% ADV participation, supporting funds up to roughly $1.36B for a 5% position. The tape is bullish — price has recovered above both the 50-day and 200-day SMAs after a Jan 2026 death cross, with RSI at 68 confirming momentum without yet signaling exhaustion.

---

Price Snapshot

---

Price History — Full Listing Period with 50/200 SMA

Price is above the 200-day SMA ($33.32) by 12%. The stock listed in Oct 2024 at ~$27.32, spiked to $42.48 within days, then spent five months grinding down to $24.48 (Apr 2025). A sharp recovery rally from the Apr 2025 lows carried the stock above both moving averages by mid-2025, peaking near $42.11 in Sep 2025. The Nov 2025–Jan 2026 sell-off forced a death cross on 15 Jan 2026, but the subsequent V-shaped bounce from $25.62 has reclaimed both MAs. This is an uptrend with high volatility — characteristic of a recently-listed, high-growth industrial name.

---

Relative Strength Since Listing

---

Momentum — RSI & MACD

RSI at 67.8 — approaching overbought territory but not there. The indicator touched deeply oversold territory (24–28) in Dec 2025–Jan 2026 before the recovery rally pushed it back to the upper band. Near-term momentum is constructive but running warm.

MACD histogram has just flipped to -0.03 from positive territory — an early warning that near-term momentum is fading after the April rally. The MACD line ($1.25) remains above signal ($1.29) by a thin margin. This does not invalidate the uptrend, but suggests the current leg may need to consolidate before pushing higher.

---

Volume, Volatility & Sponsorship

Volume has been lumpy — characteristic of a recently-listed stock with event-driven interest. The massive spikes (Sep 2025 at 12.9M shares, Aug 2025 at 14.5M, Apr 2025 at 21.4M) coincide with sharp price moves, suggesting institutional block activity. Baseline volume between events runs well below the 50-day average of 2.1M shares, pointing to a name where liquidity comes in bursts rather than continuously.

Realized volatility at 38.4% sits near the p20 boundary (37.8%) — the "calm" end of this stock's range. Post-listing vol peaked at 85% before settling into a 40–55% normal band. The current reading suggests the market is not pricing in elevated risk, which is constructive for trend-followers but also means a volatility expansion (gap up or down) could come without warning. ATR(14) at $1.18 represents roughly 3.2% of the current price.

---

Institutional Liquidity

Annual turnover of ~158% is elevated — consistent with a recently-listed stock attracting speculative and event-driven flow. ADV of $64.3M (20d) is adequate for most mid-cap fund strategies but not deep enough for mega-cap allocation sizes.

Execution friction proxy: median 60-day daily range is 2.85% — above the 2% threshold, flagging elevated intraday impact cost for large orders. Market-impact should be modeled conservatively for positions exceeding 0.5% of market cap.

The largest position that clears in five trading days at 20% ADV participation is approximately 0.63% of market cap ($67.8M). At 10% ADV, that drops to 0.32% ($33.9M). For a fund taking a 5% position, this stock supports fund sizes up to $1.36B at the more aggressive participation rate and $678M at the conservative rate.

---

Technical Scorecard & Stance

Stance: Bullish on the 3–6 month horizon (total score: +3). Waaree has reclaimed both moving averages after a textbook V-shaped recovery from the Jan 2026 lows, volatility is compressing, and the stock sits in the upper third of its 52-week range with room to the all-time high. The two levels that change the view: a decisive close above $41.20 (all-time high) confirms the bull case and invalidates the death cross as a false signal; a close below $33.05 (near the 200-day SMA) would confirm the death cross, reopen the bear case, and warrant de-risking. Liquidity is not the constraint for most mid-cap mandates — a 5% position is implementable for funds up to ~$1.36B at 20% ADV over five days — but the elevated daily range (2.85%) means execution should be patient, using VWAP or multi-day building strategies rather than aggressing into the tape.